How Much Does Wegovy Cost in 2026? Cash Price, Insurance Copay Ranges, and Cheaper Alternatives

Key Takeaways (highlighted box)

• Wegovy list price is $1,349.02 per 28-day supply (Novo Nordisk WAC, 2026), unchanged since the 2024 reduction from $1,833.
• Retail cash price at most pharmacies runs $1,300 to $1,500 per month including pharmacy markup.
• NovoCare Pharmacy direct-ship cash price is $499 per month for self-pay patients.
• With commercial insurance plus the Wegovy Savings Card, eligible patients can pay as little as $25 per fill.
• Compounded semaglutide is $179 to $279 per month at most reputable telehealth platforms.

Direct answer (40-60 words)

Wegovy costs $1,349 per month at list price, $1,300 to $1,500 retail cash, $499 through NovoCare Pharmacy direct-ship, and $25 to $500 with commercial insurance depending on your plan and savings card use. Medicare does not cover Wegovy. Compounded semaglutide is the most common cheaper alternative at $179 to $279 per month.

Table of contents

1. The 30-second answer
2. The Wegovy list price and how list pricing works
3. Retail pharmacy cash prices (Walmart, CVS, Costco, others)
4. With insurance: real copay scenarios
5. The NovoCare Pharmacy direct-ship cash price
6. The Wegovy Savings Card path to $25
7. Why Medicare and Medicaid patients pay more
8. The compounded semaglutide alternative
9. Wegovy vs Zepbound vs Ozempic on price
10. How to lower your specific Wegovy cost in 2026
11. FAQ
12. Sources
13. Footer disclaimers

The Wegovy list price and how list pricing works

Wegovy's wholesale acquisition cost (WAC) in 2026 is $1,349.02 per 28-day supply. This applies across all five doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) because Novo Nordisk prices the medication at parity regardless of strength.

The list price is what wholesalers pay Novo Nordisk before any rebates. The price you see at the pharmacy is the list price plus pharmacy markup minus any insurance-negotiated discount or savings card application.

Three reasons real prices differ from list:

1. Pharmacy benefit managers (PBMs) negotiate rebates with Novo Nordisk. A plan with a strong rebate gets a lower per-script cost than the list price; the savings flow back to the plan and partly to the patient as a lower copay.
2. Retail pharmacies add a small dispensing fee of $5 to $25 to the list price for cash-pay customers.
3. Manufacturer programs (savings card, NovoCare cash, Patient Assistance Program) reduce the price for specific eligible patients.

Novo Nordisk reduced Wegovy's list price from $1,833 to $1,349 in May 2025 in response to political pressure and to expand market access. As of Q1 2026, the price has held.

Retail pharmacy cash prices (Walmart, CVS, Costco, others)

If you walk into a retail pharmacy with a Wegovy prescription and no insurance, here is what you can expect:

Pharmacy	Wegovy cash price (28-day supply)	With GoodRx coupon
Walmart	$1,330 to $1,425	$1,275 to $1,360
CVS	$1,355 to $1,450	$1,290 to $1,380
Walgreens	$1,360 to $1,460	$1,295 to $1,390
Costco (members only)	$1,295 to $1,365	Built into price
Sam's Club (members only)	$1,310 to $1,380	$1,260 to $1,330
Mark Cuban Cost Plus Drugs	Does not carry brand-name Wegovy	N/A

Costco is consistently the lowest cash price among the major chains, which is the same pattern as Ozempic and most other brand-name medications. Membership ($60 per year base, $120 executive) usually pays for itself within one Wegovy fill for cash patients.

GoodRx coupons stack with cash payments but cannot combine with insurance. If your insurance copay is higher than the GoodRx price (rare for Wegovy, but possible on a high-deductible plan), you can choose to pay the GoodRx price instead, but the spend will not count toward your deductible.

With insurance: real copay scenarios

Commercial insurance coverage of Wegovy is more restrictive than Ozempic because Wegovy is FDA-approved only for chronic weight management. About 38% of large employer plans covered Wegovy in 2024 per Mercer survey data; that number has risen modestly through 2026.

Real plan scenarios from anonymized patient data:

Scenario 1: Employer PPO with anti-obesity medication coverage. Patient has BlueCross BlueShield through an employer that opted into AOM coverage. Wegovy on Tier 3. Copay $75 per fill after $1,500 deductible met. With Wegovy Savings Card: $25 per fill. Annual cost: roughly $300 plus deductible.

Scenario 2: Employer plan that excludes anti-obesity medications. Patient has UnitedHealthcare through an employer that excluded all weight-loss medications from formulary. Wegovy denied entirely. PA appeal denied. Annual cost if buying retail: $16,000-plus. Patient switched to compounded semaglutide at $239 per month ($2,868 per year).

Scenario 3: Marketplace silver plan. Patient has Healthcare.gov silver plan through Aetna. Wegovy on Tier 4 with 30% coinsurance after $5,000 deductible. Until deductible met, patient pays full negotiated rate ($1,180). After deductible met, copay drops to $354. With savings card: $129. Annual cost: highly deductible-dependent.

Scenario 4: High-deductible health plan with HSA. Patient has HDHP through small employer with $4,500 deductible. First two fills are full retail ($1,400 each). Once deductible met, $40 copay. Savings card brings to $25. Annual cost: roughly $3,100 plus.

Scenario 5: Self-employed, ACA bronze plan. Patient on bronze plan with $7,500 deductible and Wegovy on Tier 4. Effectively no coverage for Wegovy until deductible met. NovoCare Pharmacy at $499 per month is cheaper than running through insurance for the first half of the year. Annual cost using NovoCare: $5,988.

The lesson from these scenarios: "How much does Wegovy cost" with insurance is highly plan-specific. A test claim at a pharmacy before you fill prevents most cost surprises.

The NovoCare Pharmacy direct-ship cash price

NovoCare Pharmacy is Novo Nordisk's direct-to-patient cash program for Wegovy patients without coverage. Launched in March 2025.

Pricing (Q1 2026):

• $499 per month for the 1.7 mg dose (target maintenance for many patients)
• $499 per month for the 2.4 mg full maintenance dose
• $499 to $650 for the starter doses (0.25 mg, 0.5 mg, 1 mg) depending on partner platform

Eligibility:

• Must be a self-pay patient (no insurance, or insurance does not cover Wegovy)
• U.S. resident with U.S. mailing address
• Active prescription from a licensed U.S. provider

How it works:

• Patient receives prescription and orders through NovoCare or a partner platform
• NovoCare ships the Wegovy pen directly to the patient's address
• No insurance involved; simple flat monthly cash price

What NovoCare cash does NOT do:

• It does not lower price to $25.
• It does not stack with the Wegovy Savings Card.
• It does not count toward your insurance deductible (because no claim is filed).

For a cash-pay patient who wants brand-name Wegovy, NovoCare at $499 per month is currently the lowest legitimate brand-name option in the U.S.

For a fuller comparison, see /articles/cost-and-insurance/wegovy-savings-card/.

The Wegovy Savings Card path to $25

The Wegovy Savings Card is a Novo Nordisk copay assistance program. Eligible patients can pay as little as $25 per 28-day fill.

Eligibility:

• Commercial insurance that covers Wegovy with a copay
• U.S. resident
• Adult 18-plus
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government plan

How it works:

• Card pays up to about $225 toward your existing copay per fill
• Annual benefit cap around $1,800
• Total fill limit roughly 12 to 13 per year (terms have changed periodically; check the digital card)

The math example:

• If your copay is $250, the card pays $225 and you pay $25.
• If your copay is $400, the card pays $225 and you pay $175.
• If your copay is $50, the card pays $25 and you pay $25 (because the floor is $25).

About 60% of card users in 2024 reported a final price under $50 per fill per Novo Nordisk public statements.

For the full how-to, see /articles/general-glp1/how-do-you-get-25-wegovy/.

Why Medicare and Medicaid patients pay more

Medicare. The 2003 Medicare Modernization Act explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from Part D coverage. As of 2026, Medicare does not cover Wegovy at all unless prescribed for cardiovascular risk reduction in patients with established heart disease (a 2024 FDA expansion under the SELECT trial data) and the specific Part D plan has chosen to include it.

For most Medicare patients, the practical options are:

• NovoCare Pharmacy at $499 per month (Medicare patients can use it)
• Compounded semaglutide at $179 to $279 per month
• Patient Assistance Program (qualifying low-income patients can apply)

Medicaid. Coverage varies by state. As of 2026, about 16 states cover at least one anti-obesity medication, and around 8 of those specifically cover Wegovy. State Medicaid coverage typically requires BMI 30-plus and documentation of failed lifestyle interventions. Outside those states, Medicaid patients face the same cash-vs-compounded decision as Medicare patients.

The compounded semaglutide alternative

For patients who cannot afford brand-name Wegovy at any price tier (savings card, NovoCare, retail cash), compounded semaglutide is the most common alternative.

Pricing for compounded semaglutide:

• FormBlends compounded semaglutide: $179 to $279 per month
• Other compounding-pharmacy telehealth: $199 to $499 per month
• Local 503A compounding pharmacy: $150 to $350 per month

Important context:

• Compounded semaglutide is not FDA-approved.
• It is not interchangeable with brand-name Wegovy.
• It is drawn from a vial with a U-100 insulin syringe rather than delivered by a prefilled pen.
• It bypasses insurance, so there is no PA paperwork or formulary fight.
• The active ingredient is the same molecule as Wegovy (semaglutide).

When compounded makes financial sense:

• Your insurance does not cover Wegovy and you cannot afford $499 per month NovoCare.
• You do not qualify for the savings card (Medicare, Medicaid).
• You want predictable monthly pricing without insurance paperwork.
• Compounded providers can offer dose flexibility (drawing different amounts) that brand-name pens do not.

When brand-name makes more sense:

• Your insurance covers Wegovy and the savings card brings you to $25 per fill.
• You strongly prefer FDA-approved medications.
• You qualify for the Patient Assistance Program (free).

For the full trade-off discussion, see /articles/glp1-hub/compounded-semaglutide-for-weight-loss-complete-guide-2026.

Wegovy vs Zepbound vs Ozempic on price

For patients shopping by price across the GLP-1 class:

Medication	List price	Cash low option	Insured + savings card	Compounded equivalent
Wegovy	$1,349/mo	$499 (NovoCare)	$25	Compounded semaglutide $179 to $279/mo
Zepbound	$1,059/mo (vials), $1,086/mo (pens)	$499 (LillyDirect 2.5 mg, $599 5 mg)	$25	Compounded tirzepatide $239 to $399/mo
Ozempic	$984/mo (1 mg)	About $940 retail	$25	Compounded semaglutide $179 to $279/mo

Zepbound's vial program through LillyDirect (launched 2024) is a comparable direct-to-patient cash option at a lower price point than Wegovy's NovoCare program for the lower doses.

For comparison guidance, see /articles/comparison/wegovy-vs-zepbound/.

How to lower your specific Wegovy cost in 2026

Five-step process to find the lowest price you qualify for:

Step 1: Verify your insurance coverage. Log into your member portal and search "semaglutide" or "Wegovy" in the formulary. Note tier, PA requirements, and copay.

Step 2: If covered, enroll in the Wegovy Savings Card. Visit the Wegovy website. Enroll. Bring the card to your first fill.

Step 3: If not covered, file a PA appeal. Have your provider submit BMI documentation, comorbidity records, and failed-alternative documentation.

Step 4: If appeal denied, evaluate NovoCare cash vs compounded. $499 per month brand-name through NovoCare vs $179 to $279 per month compounded. Compounded is roughly 50% cheaper but is not FDA-approved.

Step 5: Apply for the Novo Nordisk Patient Assistance Program if low-income. Income below 400% FPL with no Wegovy coverage can qualify for free Wegovy.

This sequence (insurance → savings card → appeal → NovoCare → compounded → PAP) covers every legal lower-cost path for Wegovy in 2026.

FAQ

How much does Wegovy cost without insurance? Retail cash price at most pharmacies is $1,300 to $1,500 per month. NovoCare Pharmacy direct-ship is $499 per month for self-pay patients. Compounded semaglutide is $179 to $279 per month at reputable telehealth platforms.

How much does Wegovy cost with insurance? Typically $25 to $500 per month depending on your plan. With the Wegovy Savings Card, eligible commercial-insured patients can pay as little as $25 per fill. Plans that exclude anti-obesity medications cover none of the cost.

Why is Wegovy so expensive? Wegovy is a brand-name injectable manufactured by Novo Nordisk under patent. There is no generic version. List price reflects R&D costs, manufacturing, distribution, and Novo Nordisk's pricing strategy. The list price was reduced from $1,833 to $1,349 in May 2025.

Is there a cheaper version of Wegovy? Yes. NovoCare Pharmacy direct-ship at $499 per month is the cheapest brand-name option. Compounded semaglutide at $179 to $279 per month is the cheapest legitimate non-brand option.

How much is Wegovy at Walmart? Walmart cash price is $1,330 to $1,425 per month. With insurance, Walmart processes the same negotiated rate as other major retail pharmacies, so the variation by chain is usually less than $50.

Does Medicare cover Wegovy? Generally no. Medicare Part D does not cover Wegovy for weight loss. As of 2024, Wegovy can be covered for cardiovascular risk reduction in patients with established heart disease, if the specific Part D plan has chosen to include it. Most Medicare patients pay through NovoCare or compounded.

How do I get the $25 Wegovy price? Enroll in the Wegovy Savings Card on the Wegovy website and use it alongside commercial insurance that already covers Wegovy. The card reduces eligible copays to as low as $25 per 28-day fill.

Is compounded semaglutide really cheaper than Wegovy? Yes, by a large margin for cash-pay patients. Compounded semaglutide at $179 to $279 per month vs Wegovy retail cash at $1,300 to $1,500. The trade-off is FDA approval status and the requirement to draw your own dose from a vial.

How much will Wegovy cost without coverage in 2026? NovoCare Pharmacy at $499 per month, which is $5,988 per year. Retail cash without NovoCare is $1,349 per month list, totaling $16,188 per year. Compounded semaglutide is $179 to $279 per month or $2,148 to $3,348 per year.

Will the price of Wegovy go down? Possibly. Novo Nordisk reduced the list price by 26% in May 2025. Further reductions depend on negotiated outcomes from the Inflation Reduction Act drug pricing program (Wegovy is not currently in scope for negotiation but may become eligible in later cycles).

Does Costco sell Wegovy cheaper? Yes, by about $50 to $100 per month vs Walmart and CVS. Costco's pricing model passes wholesale rates through with a lower markup. Membership is required ($60 per year base, $120 executive). Costco's pricing covers cash-pay; insured pricing is similar across chains.

Can I split Wegovy doses to make a fill last longer? No. Each Wegovy pen is dosed at a fixed amount per click. Patients cannot mathematically split a 2.4 mg pen into multiple smaller doses. With compounded semaglutide drawn from a vial, dose splitting is technically possible and is one reason some patients prefer the compounded format for budget reasons. Always follow your provider's dosing guidance.

Sources

1. Novo Nordisk. Wegovy (semaglutide injection 2.4 mg) Prescribing Information, revised 2024.
2. Novo Nordisk. Wegovy wholesale acquisition cost announcement, May 2025.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
5. Novo Nordisk. NovoCare Pharmacy direct-to-patient program announcement and pricing, 2025.
6. Novo Nordisk. Wegovy Savings Card Terms and Conditions, 2026.
7. Mercer National Survey of Employer-Sponsored Health Plans. Coverage trends for anti-obesity medications, 2024.
8. Centers for Medicare and Medicaid Services. Medicare Part D coverage rules and 2024 updates for cardiovascular indications.
9. Kaiser Family Foundation. State Medicaid coverage of obesity medications: a 50-state survey, 2024.
10. American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
11. GoodRx Research. Pharmacy pricing data for GLP-1 medications, 2024 to 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. NovoCare and LillyDirect are services of their respective owners. Walmart, CVS, Walgreens, Costco, Sam's Club, GoodRx, and Mark Cuban Cost Plus Drugs are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.